There will be a new two-agency approach for medical device procurement in public hospitals.
Value of the 55% stake in Integrated Control Technology not disclosed.
Feasibility study under way for offshore project, expected to take 24 months.
Agri-emission research funders say evidence of Zest Biotech value is unconvincing.
The One in Longhorn Partnership Fund promoted returns of 50%.
UPDATE: Report of potential float follows informal proposal in last two years.
How the money-go-round on funding and debt for the project works.
Ormiston Rise’s New York backer says it’s exempt from New Zealand law.
Continued spread could reduce returns by $1.60/tray according to earlier Zespri modelling.
Founder Michael Lawson rejoins forces with Lance Wiggs to take big plan to the world.